ࡱ> GJDEFc vbjbjBB  f fh!!!!!"""$l&"b()***S,>,, &(((((($ L!,1,1,",,L!!**a444,!*!*&4,&44(*?R- pw0zK//KK!. ,,4,,,,,LL 2,,,,,,,K,,,,,,,,, : This section contains information about enteral nutrition products, program coverage and a list of products. The information provided in this section applies to the products included on the following spreadsheet:  HYPERLINK "http://files.medi-cal.ca.gov/pubsdoco/publications/masters-mtp/part2/enteralnutrition.xls" List of Enteral Nutrition Products The products included on the spreadsheet are eligible for Medi-Cal reimbursement. The products are grouped by the following product categories: Elemental and Semi-Elemental Metabolic Specialized Specialty Infant Standard Beneficiaries must meet the medical criteria for the product category specific to the product requested. Program Coverage Enteral nutrition products may be covered upon authorization when used as a therapeutic regimen to prevent serious disability or death in patients with medically diagnosed conditions that preclude the full use of regular food (California Code of Regulations [CCR], Title 22, Section 51313.3). Enteral nutrition products covered are subject to the Medi-Cal List of Enteral Nutrition Products and utilization controls (Welfare and Institutions Code [W&I Code], Sections 14132.86, 14105.8 and 14105.395). Products on the Medi-Cal List of Enteral Nutrition Products are separately covered upon authorization for eligible Medi-Cal fee-for-service outpatients when supplied by a pharmacy provider upon the prescription of a physician within the scope of his or her practice as defined by California laws. Eligibility Requirements To receive reimbursement, the beneficiary must be eligible for Medi-Cal fee-for-service on the date of service. Medi-Cal Managed Care Plans Beneficiaries enrolled in Medi-Cal managed care plans (MCPs) must receive Medi-Cal enteral nutrition benefit from plan providers. MCPs are required to provide or arrange for medically necessary enteral nutrition products as a covered Medi-Cal benefit. Each MCP is unique in its billing and service procedures. Providers must contact the individual MCP for billing instructions. CCS or GHPP The List of Enteral Nutrition Products and coverage criteria applies to Medi-Cal claims for beneficiaries enrolled in the California Childrens Services (CCS) or Genetically Handicapped Persons Program (GHPP). Inpatient Enteral nutrition products provided to inpatients receiving inpatient hospital services are included in the hospitals reimbursement made under the CCR, Title 22, Section 51536. These products are not separately reimbursable. Nursing Facilities or Enteral nutrition products provided to inpatients receiving Nursing Intermediate Care Facilities Facility Level A services or Nursing Facility Level B services are not separately reimbursable. Enteral nutrition products provided to patients in an Intermediate Care Facility for the Developmentally Disabled (ICF/DD), Intermediate Care Facility for the Developmentally Disabled/Habilitative (ICF/DD-H) or Intermediate Care Facility for the Developmentally Disabled/Nursing (ICF/DD-N) are reimbursed as part of the facilitys daily rate and are not separately reimbursable (CCR, Title 22, Sections 51510.1, 51510.2 and 51510.3). The Department of Health Care Services (DHCS) shall recover overpayments for non-covered services, which include 100 percent of the ingredient cost and professional fee pursuant to CCR, Title 22, Section 51488.1(a)(2). Equipment-Related Supplies For enteral feeding supplies, refer to the Medical Supply Products section of this manual for billing codes and additional information. Non-Coverage The following nutrition products are not covered by Medi-Cal: Regular food, including solid, semi-solid, blenderized and pureed foods Common household items Regular infant formula as defined in the Federal Food, Drug and Cosmetic Act (FD&C Act) Shakes, cereals, thickened products, puddings, bars, gels and other non-liquid products Thickeners Products for assistance with weight loss Vitamin and/or mineral supplements, except for pregnancy and birth up to 5 years of age (Refer to the appropriate contract drugs list section in this manual for more information). Enteral nutrition products used orally as a convenient alternative to preparing and/or consuming regular solid or pureed foods Other Health Coverage Refer to the Other Health Coverage (OHC) section in this manual for OHC billing information. Medicare Covered Services Medicare covered enteral nutrition products must be billed to Medicare before billing Medi-Cal for dual-eligible beneficiaries with Medicare Part B coverage. Additional information is included in the Medicare/Medi-Cal Crossover Claims section in this manual. To ensure refills are delivered prior to exhaustion of existing supplies, providers may overlap the date of service up to five days on crossover claims billed for the following HCPCS codes: HCPCS CodeDescriptionB4034 B4036Enteral feeding supply kits, tubing and tubesB4081 B4083Enteral feeding supply kits, tubing and tubesB4087 B4088Enteral feeding supply kits, tubing and tubesB4102Enteral formula, for adultsB4103Enteral formula, for pediatricsB4150Enteral formulasB4152 B4155Enteral formulas HCPCS CodeDescriptionB4157 B4162Enteral formulasB9998NOC for enteral supplies Providers must verify that the previous months supplies are almost exhausted prior to shipping a refill of the product Providers should contact the Medicare carrier for coverage and billing instructions. Prescription Requirement A written prescription signed by a physician is required for authorization of all enteral nutrition products The physicians full name, address and telephone number must be clearly supplied if not pre-printed on the prescription form. Authorization All enteral nutrition products require the beneficiarys pharmacy provider to submit either a Treatment Authorization Request (TAR) or a Service Authorization Request (SAR) for authorization. The required information to demonstrate that both medical criteria and product criteria are met, must be supplied on or attached to the authorization request as documented in the beneficiarys medical record. The product number approved on a TAR or SAR must be the same product number dispensed and billed. Authorization for all enteral nutrition products is limited to billing up to a 31-day supply per claim, based on documented caloric and nutrient requirements per day, converted to a 31-day supply. Note: Billing quantities must be appropriate for the product size (quantity) dispensed and product description on the List of Enteral Nutrition Products. Rounding quantities on claims for enteral nutrition products is not permitted (for example: billing a quantity of 240 ml for a package size of 237 ml is not allowed). Refer to the TAR Completion section of this manual for additional TAR information. TARs for Medi-Cal beneficiaries must be submitted to the TAR Processing Center. Refer to the California Childrens Services (CCS) Program Service Authorization Request (SAR) section of this manual for instructions for submitting a SAR or contact a California Childrens Services (CCS)/Genetically Handicapped Persons Program (GHPP) Program representative. Product Criteria The enteral nutrition product requested on an authorization must be on the List of Enteral Nutrition Products and the beneficiary must meet the medical criteria for the specific product category and, if applicable, product-specific criteria. Products are listed in one or more of the following enteral nutrition product categories: Elemental and semi-elemental (contain partially or fully broken down macronutrients) Metabolic (indicated for inborn errors of metabolism diagnosis) Specialized (disease-specific with intact macronutrients and modulars) Specialty infant (indicated for specific diagnosis or conditions) Standard (contain intact macronutrients and be nutritionally complete) Refer to the List of Enteral Nutrition Products for product-specific criteria. Medical Criteria Refer to the appropriate product category type for the specific medical criteria that must be met. Standard Products To be considered for authorization of standard products (contain intact macronutrients) that are on the List of Enteral Nutrition Products, the beneficiary must meet one of the criteria below. Note: Refer to the List of Enteral Nutrition Products for product-specific criteria that may also apply. A documented medical diagnosis that requires enteral nutrition products administered through a feeding tube For enteral nutrition products administered orally, beneficiary must meet one of the following: Have a documented chronic medical diagnosis and unable to meet their nutritional needs with dietary adjustment of regular or altered-consistency (soft or pureed) foods. There must be clinical indicators identified and documented that support the beneficiary is nutritionally at risk. Beneficiaries (21 years of age and older) with a medical condition and adequate nutrition is not possible with dietary adjustment of regular or altered-consistency (soft or pureed) foods. There must be documentation beneficiary is nutritionally at risk with one of the following anthropometric measures: Involuntary loss of 10 percent or more of usual body weight within six months Involuntary loss of 7.5 percent or more of usual body weight within three months Involuntary loss of 5 percent or more of usual body weight in one month Body mass index less than 18.5 kg/m2 Beneficiaries under 21 years of age with documented clinical signs and symptoms including anthropometric status indicators (stunting, wasting or underweight) of nutritional risk. Standard and modified growth charts should be used to document nutritional need and patient deficiency. Severe swallowing or chewing difficulty due to one of the following: Cancer in the mouth, throat or esophagus Injury, trauma, surgery or radiation therapy involving the head or neck Chronic neurological disorders Severe craniofacial anomalies Transitioning from parenteral or enteral tube feeding to an oral diet Specialized Products To be considered for authorization of specialized nutrition products that are on the List of Enteral Nutrition Products, documentation must include evidence to support the beneficiary meets one of the standard products medical criteria and the criteria specific to the product requested. The beneficiary must also meet the criteria below specific to the product type requested. Refer to the List of Enteral Nutrition Products for product-specific criteria that may also apply. For disease-specific products administered orally or through a feeding tube, the beneficiary must have a documented medical diagnosis, specific to the product requested and meet one of the standard products medical criteria. For diabetic products, the beneficiary must have a documented diagnosis of hyperglycemia or diabetes and HbA1c (A1c) value measured within six months of the authorization request. The diagnosis name and ICD-10-CM diagnosis code and the HbA1c value must be clearly supplied on the authorization request. For renal products, one of the following indicators measured within six months of the request must be clearly supplied on the authorization request for individuals 18 years and older. Blood serum potassium BUN levels greater than 20 mg/dl Urine Creatinine greater than 26 mg/kg/day for men or greater than 20 mg/kg/day for women Glomerular Filtration Rate (GFR) less than 60mL/min/1.73m2 For hepatic products, results of liver function test measured within six months of the request must be clearly supplied on the authorization request. For carbohydrate modular products administered orally or through a feeding tube, there must be documented clinical evidence to support the beneficiary is unable to meet caloric nutritional need with the current use of an enteral nutrition product For lipid (fat) modular products administered orally or through a feeding tube, the beneficiary must meet one of the following: Have a documented diagnosis of inability to digest or absorb conventional fats Have a documented diagnosis of uncontrolled seizure or other neurological disorder that cannot otherwise be medically managed For protein modular products administered orally or through a feeding tube, there must be documented clinical evidence to support the beneficiary is unable to meet protein requirement with current use of a high protein enteral nutrition product. Elemental and To be considered for authorization of elemental or semi-elemental Semi-Elemental Products products that are on the List of Enteral Nutrition Products and administered orally or through a feeding tube, the beneficiary must meet one of the criteria below. Note: Refer to the List of Enteral Nutrition Products for product-specific criteria that may also apply. In rare cases, off-age products may be authorized if medical justification for off-age use is documented and attached to the authorization request. Have an intestinal malabsorption diagnosis (ICD-10-CM codes K90.0 K90.9 and K91.2); lactose intolerance alone is excluded. The diagnosis name and ICD-10-CM code must be clearly supplied on the authorization request. Have a chronic medical diagnosis and present clinical signs and symptoms of inability to absorb nutrients or to tolerate intact protein that cannot otherwise be medically managed. The beneficiary must have a history of use with a standard or specialized disease-specific enteral nutrition product that failed to provide adequate nutrition unless such products are medically contraindicated. Metabolic Products Authorization of metabolic products on the List of Enteral Nutrition Products administered orally or through a feeding tube is restricted to beneficiaries with a diagnosis of inborn errors of metabolism (genetic, metabolic condition). Refer to the List of Enteral Nutrition Products for product-specific criteria that may also apply. EXCEPTION: For metabolic ketogenic formulas, authorization may also be considered when documentation confirms the beneficiary meets one of the criteria below: Have seizures that are refractory to standard anti-seizure medications Have a chronic medical diagnosis where a ketogenic diet is medical necessary and a history of use with a product in another enteral nutrition category that failed to provide adequate nutrition unless such products are medically contraindicated. Note: For adult beneficiaries 21 years of age and older, authorization is restricted to the ICD-10-CM diagnosis codes on the tables below. The ICD-10-CM code and diagnosis name must be clearly supplied on the authorization request as documented in the beneficiarys medical record. ICD-10-CM CODEDIAGNOSIS: Inborn Errors of Metabolism (IEM)E70.0Classical phenylketonuria E70.1Other hyperphenylalaninemiasE70.20 E70.29Disorders of tyrosine metabolismE70.30 E70.39AlbininsmE70.40 E70.49Disorders of histidine metabolismE70.5Disorders of tryptophan metabolismE70.8Other disorders of aromatic amino-acid metabolismE70.9Disorder of aromatic amino-acid metabolism, unspecifiedE71.0Maple-syrup urine diseaseE71.110 E71.19Other disorders of branched-chain amino-acid metabolism ICD-10-CM CODEDIAGNOSIS: Inborn Errors of Metabolism (IEM)E71.2Disorder of branched-chain amino-acid metabolism, unspecifiedE71.30Disorder of fatty-acid metabolism, unspecifiedE71.310 E71.318Disorders of fatty-acid oxidationE71.32Disorders of ketone metabolismE71.39Other disorders of fatty-acid metabolismE71.40Disorder of carnitine metabolism, unspecifiedE71.42Carnitine deficiency due to inborn errors of metabolismE71.50 E71.548Peroxisomal disordersE72.00 E72.09Disorders of amino-acid transportE72.10 E72.19Disorders of sulphur-bearing amino-acid metabolismE72.20 E72.29Disorders of urea cycle metabolismE72.3Disorders of lysine and hydroxylysine metabolismE72.4Disorders of ornithine metabolismE72.50 E72.59Disorders of glycine metabolismE72.8Other specified disorders of amino-acid metabolismE72.9Disorder of amino-acid metabolism, unspecifiedE74.00 E74.9Other disorders of carbohydrate metabolismE75.00 E75.6Disorders of sphingolipid metabolism and other lipid storage disordersE76.01 E76.9Disorders of glycosaminoglycan metabolismE77.0 E77.9Disorders of glycoprotein metabolismE84.0 E84.9Cystic fibrosis E88.40 E88.49Mitochondrial metabolism disorders Specialty Infant Products The specialty infant products are grouped in the following product types: Premature and Low Birth Weight Products Human Milk Fortifier Extensively Hydrolyzed Products (EH) Amino Acid-Based Products (100 percent) Renal Products (Renal) Chylothorax or long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD deficiency) Products For infant metabolic products, refer to the products listed under the metabolic category. Refer to the amino acid-based products (100 percent) for products used in fat malabsorption. Note: Regular infant formula products as defined in the Federal Food, Drug and Cosmetic Act (FD&C Act) are not covered. Specialty infant products are restricted for use at time of birth through age 12 months except when one of the following criteria has been met: Corrected age (CA) applies only to infants born prior to 37 weeks gestation. For example, if birth date is 36 weeks gestation (four weeks early), remove four weeks from actual age (AA) since birth to get CA. CA is always younger than AA. Use beyond age 12 months (including CA when applicable) requires documented medical justification clearly supplied on, or with, the authorization request, as documented in the infants medical record. Maximum age at time of authorization is nine months plus 29 days; CA applies, except when noted. Note: Quantities for specialty infant enteral nutrition products based on sole source nutrition are approved up to six months of age except infants that do not make expected progress in advancement to solid foods, usually associated with a lessening in kcals/kg of body weight need recognized by American Academy of Pediatrics. Additional medical documentation, stated clearly on or with the authorization request, as documented in the infants medical record is required. Authorization for specialty infant products are limited to a maximum two-month term, except when noted. To be considered for authorization of specialty infant products that are on the List of Enteral Nutrition Products and administered orally or through a feeding tube, the beneficiary must meet the criteria listed below specific to the product and/or product type requested: For premature and low birth weight products: Products 20 or 22 kcal/ounce are limited to beneficiaries born prior to 37 weeks gestation or birth weight less than 3500 grams Products 24 or 30 kcal/ounce are authorized for one month only per request and limited to current weight (at time of dispensing) less than 3500 grams For human milk fortifier products: Authorization is limited to one month only per request for beneficiaries with current weight less than 3600 grams and meet one of the following: Receiving only human milk and no other infant nutrition product (formula) used at the same time. Breast fed or receiving human milk in combination with infant nutrition product (formula) administered only through a feeding tube Breast fed or receiving human milk in combination with infant nutrition product (formula) administered orally when one of the following conditions is currently documented and met: Infant is at risk for necrotizing enterocolitis Mother of infant is establishing milk supply Human milk intake is increasing Note: Calculate 31-day supply limit based on expected infant weight gain of 33 34 grams/day during an authorization term. For extensively hydrolyzed products without probiotics, the beneficiary must meet one of the criteria listed below. Product specific criteria may also apply. Current diagnosis of cows milk protein allergy (CMPA) Severe food allergy indicating a sensitivity to intact protein For extensively hydrolyzed products with probiotics, the beneficiary must have a current diagnosis of cows milk protein allergy (CMPA) or intolerance to breast milk or regular infant formula and meet all of the following: No immune function disorder Born full term (between 37 weeks and 42 weeks) No indwelling venous catheters For amino acid-based (100 percent) products without probiotics, beneficiaries must meet one of the following: Documented intolerance to breast milk or infant formula due to one of the following: A clinical diagnosis of severe cows milk protein allergy (CMPA), multiple food protein allergies, or eosinophilic GI disorder Protein maldigestion or malabsorption diagnosis where extensively hydrolyzed specialty infant products have tried and failed A clinical diagnosis of gastrointestinal (GI) disorders such as short bowel syndrome of GI impairment Extensively hydrolyzed (semi-elemental) products are contraindicated For initial request, documented in hospital use prior to discharge, establishing the need for the product. Must meet one of the other criteria for subsequent request. Documented clinical fat malabsorption or steatorrhea diagnosis not effectively addressed by breast milk, regular infant formula and extensively hydrolyzed protein. Authorization may also be considered for fat malabsorption or steatorrhea as a secondary diagnosis associated with cystic fibrosis, short-bowel syndrome or other related clinical conditions. For amino-based (100 percent) products with probiotics, beneficiaries must meet one of the above listed criteria (5a d) AND all of the following: No immune function disorder Born full term (between 37 weeks and 42 weeks) No indwelling venous catheters or post-pyloric feeding type For renal products, beneficiaries must meet one of the following: Renal function impairment Hypercalcemia Hypocalcemia due to hyperphosphatemia For Chylothorax or LCHAD deficiency product type beneficiaries must have one of the following documented diagnoses: Chylothorax Long-chain-3-hydroxyacyl-CoA-dehydrogenase deficiency (LCHAD deficiency) Cystic Fibrosis Mitochondrial disorder Documentation Requirements All of the clinical and product information listed below, as documented in the beneficiarys medical record, must be clearly supplied on the authorization request, or as an attachment to the request signed and dated by the physician. The physicians name, address and telephone number must also be clearly supplied on the request. Medical diagnosis name related to the product requested Note: ICD-10-CM codes are required for certain product category types and/or diagnosis. Refer to the product category medical criteria specific for the product requested. Age, height (length), weight, body mass index (BMI) Biochemical, clinical and/or dietary indicators related to the request for product Daily caloric requirements Estimated duration of need for the enteral nutrition product and/or nutrition care plan Route of administration Product label name being prescribed Product package size (ml or gm) Product caloric density (kcal/ml or kcal/gm) Product 11-digit Medi-Cal billing number Special Documentation The documentation must be dated as follows: Instructions For standard, elemental, semi-elemental and specialized products, documentation must be dated within three months at the time of TAR or SAR submission. For metabolic products, documentation must be dated within six months at the time of TAR or SAR submission. For specialty infant products, documentation must be dated within two months at the time of TAR or SAR submission. Some products require additional documentation. Refer to the product category medical criteria specific for the product requested in this section and/or the product-specific criteria on the List of Enteral Nutrition Products. Billing Requirements Enteral nutrition products are pharmacy-only dispensed and billed using the 11-digit Medi-Cal billing number on the National Council for Prescription Drug Program (NCPDP) electronic transaction or Pharmacy 30-1 claim form. Claims for enteral nutrition products must include the Medi-Cal billing number as published on the List of Enteral Nutrition Products spreadsheet. The product number approved on a TAR or SAR must be the same product number dispensed and billed. Enteral nutrition products may not be billed on a Compound Pharmacy Claim Form (NCPDP or 30-4). Billing Limitations Claims billed for enteral nutrition products are limited to no more than a 31-day supply. A 31-day supply is defined as the beneficiarys daily caloric requirement for product (specified by the physician on the prescription), multiplied by 31 days, divided by caloric density of product (kcal/milliliter of liquid product, or kcal/gram of powdered product) and rounded up to the smallest available package size (can, bottle, bag, or brikpak). Rounding up does not include rounding up to six packs or full cases of product. See documentation requirements in the previous section to establish 31-day supply. Reimbursement The amount reimbursed to providers for enteral nutrition products shall not exceed the published estimated acquisition cost (EAC) plus a 23 percent markup (W&I Code, Section 14105.85). Refer to the List of Enteral Nutrition Products spreadsheet for the published EAC. Contracted Products The Department of Health Care Services (DHCS), pursuant to the W&I Code, Section 14105.8, has negotiated non-exclusive contracts for a maximum acquisition cost (MAC) for specified enteral nutrition products, with interested manufacturers. The contractors guarantee to Medi-Cal pharmacy providers the purchase of the contracted products at or below the MAC, upon request, for dispensing to eligible Medi-Cal fee-for-service outpatients. Contracted products are listed with a MAC price. Suppliers may be contacted for identification of routes for obtaining MAC prices at: MAC Price SupplierTelephone NumberAbbott Nutrition1-800-558-7677Cambrooke Therapeutics1-866-456-9776Gerber Products Company dba Nestle Infant Nutrition1-973-593-7500Global Health Products, Inc.1-800-638-2870Kate Farms, Inc.1-805-845-8446Mead Johnson Nutrition1-800-457-3550Nestl HealthCare Nutrition1-800-422-ASK2Nutricia North America1-800-365-7354Solace Nutrition, LLC1-888-876-5223Vitaflo USA1-773-255-2223     enteral  PAGE 2 enteral Enteral Nutrition Products  PAGE 1 2 Enteral Nutrition Products ____2015 2 Enteral Nutrition Products May 2017 enteral  PAGE 2 2 Enteral Nutrition Products August 2019 Enteral Nutrition Products ____2015 enteral  PAGE 4 enteral  PAGE 3 2 Enteral Nutrition Products ____2015 2 Enteral Nutrition Products March 2017 enteral  PAGE 4 enteral  PAGE 5 2 Enteral Nutrition Products May 2017 2 Enteral Nutrition Products ____2015 enteral  PAGE 5 2 Enteral Nutrition Products ____2015 2 Enteral Nutrition Products May 2019 enteral  PAGE 6 2 Enteral Nutrition Products April 2015 2 Enteral Nutrition Products ____2015 enteral  PAGE 7 2 Enteral Nutrition Products November 2017 enteral  PAGE 8 enteral  PAGE 9 2 Enteral Nutrition Products March 2017 2 Enteral Nutrition Products: An Overview March 2014 enteral  PAGE 9 2 Enteral Nutrition Products November 2017 enteral  PAGE 10 2 Enteral Nutrition Products November 2017 enteral  PAGE 12 enteral  PAGE 11 2 Enteral Nutrition Products ____2015 2 Enteral Nutrition Products November 2017 enteral  PAGE 12 2 Enteral Nutrition Products March 2017 enteral  PAGE 13 2 Enteral Nutrition Products ____2015 2 Enteral Nutrition Products November 2017 enteral  PAGE 14 2 Enteral Nutrition Products November 2017 2 Enteral Nutrition Products ____2015 enteral 12 enteral  PAGE 15 2 Enteral Nutrition Products ____2015 2 Enteral Nutrition Products May 2017 enteral  PAGE 16 enteral 16 2 Enteral Nutrition Products February 2020 enteral  PAGE 17 2 Enteral Nutrition Products August 2019 BCTlmn > ? @ b c d e     * ; C D øÕÈ{naWWWWWWWWMhQVhc]~6^JhT=hc]~6^JhLu6hc]~^JmH sH h &khc]~^JmH sH hkGhkG^JmH sH hkGhc]~^JmH sH hI)shc]~0J6^JmH sH $jhc]~6U^JmH sH hc]~6^JmH sH jhc]~6U^JmH sH hMhc]~^JmH sH hhc]~^JmH sH hc]~^JmH sH hT=hc]~^Jd e   * ; D e! & F 8XX'dQ]^X`gdkG# & F 8XXx'dQ]^X`gdkGx'dQ]gdc]~'dQ]gdkG & FX'dQ]^X`gdkGx'dQ]gdkG D E   ȿqg_S_Ghhc]~]mH sH hhc]~]mH sH hhc]~]h,hc]~6]hdrhc]~6]mH sH hc]~]mH sH hY:hc]~6]h~Nhc]~]hc]~ hL*hc]~h$hc]~mH sH hc]~mH sH  h$hc]~hT=hc]~^JhT=hc]~5^JhT=hc]~OJQJ^Jhc]~OJQJ^JhQVhc]~^JmH sH hc]~^JmH sH D E q y  0 0$0 ]^0 `gdQV0 ^0 gdc]~0 'dQ^0 gdc]~ 'dQgdkG0 'dQ^0 `gdc]~]gdc]~ 'dQgdc]~'dQ]gdc]~   ' / B I b c d p q ۻƯ협yoaVVMhj&ihc]~^JhkG6^JmH sH hQVhc]~6^JmH sH hc]~^JmH sH h &h^JmH sH h &hc]~mH sH  hhc]~hhc]~mH sH h &hc]~6mH sH hhc]~6mH sH h~Nhc]~mH sH hc]~6mH sH hQVhc]~6mH sH hEhc]~mH sH  hEhc]~hc]~mH sH hhmH sH   . 7 8 H S x y >?pqr   Ƹvh ^JmH sH ha^JmH sH hm&hc]~^JmH sH hkGOJQJ^Jhc]~OJQJ^Jhm&hc]~OJQJ^Jhm&hc]~OJQJ\^JhOJQJ\^JhUahc]~^J hc]~^Jh.@hc]~^JmH sH hc]~^JmH sH h.@hc]~^J. pqr   7 N 'dQgdkG0 'dQ^0 `gdY0 'dQ^0 `gdkG0 'dQ^0 `gdQV0 'dQ^0 `gdc]~0 ]^0 `gdb[ &'./89@Wbjvźzzmz`Z hY^JhC]hY^JmH sH h,hY^JmH sH h,hY^Jh$1hY^JmH sH h$1hY^Jh\=hY^JmH sH hY^JmH sH hQVhY6^JhY6^JmH sH hQVhY6^JmH sH hm&hY^JmH sH hT=hY^JmH sH hT=hY^Jh ^JmH sH #/67ST JKLSlmúôuuuuuuuuuuuuhhhYOJQJ^JhK1hYOJQJ^JhYOJQJ^JhK1hYOJQJ^JsHhYOJQJ^JtHhBhY^JmH sH  hY^JhT=hY^JhY^JmH sH htg6hY^JmH sH htg6hY^Jhtg6hYmH sH  htg6hYhT=hYmH sH (7ghCDE6w 00 x'dQ^0 `gdkG0 'dQ^0 `gdQV0 'dQ^0 `gdY0 'd Q ]^0 gdY 0 ]^0 gdY]gdkGN 'dQ^N `gdY fghBCDE` 56pviii[iiNhRhR^JmH sH hhR>*^JmH sH hhR^JmH sH hhR5^JmH sH hT=ha1^JhC]hC]^JmH sH hY6^JmH sH hm&hY6^JmH sH hm&hY^JmH sH hY^JmH sH  hPWhY^JmH nH sH tH hY^JmH nH sH tH hhYOJQJ^JhYOJQJ^Jpq}~EPy,- !"#$%?+BCD (´ܦܦܴܦ|hfhROJQJ^Jh*hROJPJQJ^JhlhR5OJQJ^JhhR6^JmH sH hhR5^JmH sH h0chR^JmH sH h(hR^JmH sH hhR^JmH sH hRhR^JmH sH hR^JmH sH 06~EPy-"#$%C0 'dQ^0 `gdkG0 'dQ^0 `gdR & F 'dQ^`gdkG & F x'dQ^`gdkGCD (VbM !3x$If^3gdnVkd=$$Ifl0 G$I t644 la ytu !x$IfgdQ !3x$If^3gdR0 x'dQ^0 gdR 'dQgdkG(VWe!23ARSTUVamn{|Ȼ䢕~~obUbUhfhc]~OJQJ^Jhx_hc]~OJQJ^Jhnhc]~OJPJQJ^Jhlhc]~5OJQJ^JhT=ha1^JhU%h=^JmH sH hU%^JmH sH hRh*OJPJQJ^Jhfh*OJQJ^JhRhnOJPJQJ^JhfhnOJQJ^JhRhROJPJQJ^JhfhROJQJ^J VWe+Vkd$$Ifl0 G$I t644 la ytu !x$IfgdQ !3x$If^3gdRVkd$$Ifl0 G$I t644 la ytuVkdK$$Ifl0 G$I t644 la ytu !x$IfgdQ !3x$If^3gdR+Vkd$$Ifl0 G$I t644 la ytu !x$IfgdQ !3x$If^3gdRVkd$$Ifl0 G$I t644 la ytu!23ARVkdY$$Ifl0 G$I t644 la ytu !x$IfgdQ !3x$If^3gdRRSTUVam~m !x$Ifgd=* !3x$If^3gd=*0 'dQ^0 `gdQVVkd$$Ifl0 G$I t644 la ytumn|+Vkdg$$Ifl0 G$I t644 la yt=* !x$Ifgd=* !3x$If^3gd=*Vkd $$Ifl0 G$I t644 la yt=*&'(|}~ ?@Ǻ͢͏͏͂͂͢uhhT=h ^JmH sH hhc]~^JmH sH hEhc]~^JmH sH hT=hc]~^JhT=hc]~5^Jh ^JmH sH hh \^JmH sH hhc]~^JmH sH  hc]~^Jhc]~^JmH sH hfhc]~OJQJ^Jhx_hc]~OJQJ^JhRhc]~OJPJQJ^J''(}~ududWWW 'dQgd 0 'dQ^0 gdc]~ 'dQgdkGVkd$$Ifl0 G$I t644 la yt=* !x$Ifgd=* !3x$If^3gd=* @) * R!S!"":#;#O$'dQ^`gdc]~0 'dQ^0 `gdc]~ 'dQgd 0 ^0 gdc]~ 'dQgdkG0 'dQ^0 gdc]~ 0 ^0 `gdc]~CUXq  ) * / < V [ f g !!2!4!E!F!Q!R!S!Y!!!"""ڴڮڤڎhc]~6^JmH sH hc]~5^JmH sH h ^JmH sH  hc]~^Jhh ^JmH sH hT=hc]~^JmH sH hT=hc]~6]^Jhc]~^JmH sH hT=hc]~^JhT=hc]~5^Jhnh ^J3"""""##"#8#9#:#;#H#####$$1$5$6$7$8$>$?$M$N$O$P$Q$R$c$g$Ǻᬟ͖͖͌rh[hxzhA^JmH sH hT=hA5^JhT=hJW^JmH sH hT=hkG^JmH sH hR^JmH sH hm&hc]~^Jhm&hc]~^JmH sH hm&hc]~6^JmH sH hhc]~^JmH sH  hc]~^Jhc]~^JmH sH hT=hc]~6^JhT=hc]~^JhT=h ^Jh:hc]~^JmH sH !O$P$Q$R$U%V%%&E&&&'k & F @ ^`gdkG & F @ x'dQ^`gdkG0 x'dQ^0 gdkG 0 ]gdA0 'dQ^0 `gdA0 'dQ^0 `gdQV0 'dQ^0 `gd g$$$$$$$$%%S%T%U%V%%%%&&&&&D&E&W&Z&b&&&&&&&&'''''#'E'd'e'f'g'h'x'y''¸¸¸¸¸¸縞hhA^JmH sH hhA5^JmH sH h%hA^JmH sH h@94hA^JmH sH hA^JmH sH hT=hA^JmH sH h'YhAOJQJ^JhA6^JmH sH hA^JmH sH hT=hA^J hA^J0''e'f'g'h''''(()~x'dQ^`gdA ]gdAO ]^O `gdA 'dQ^` gdA0 'dQ^0 `gdA0 'dQ^0 gdA 'dQgdA '''''((((('(X(z(((((((((((()))()ôêê{qh\hVhhhJhAOJQJ^JtH hA^JhvhA6]^JhvhA^Jh@94hA5^Jh hA5^Jh?fxhAOJQJ^JhvhAOJQJ^JhA6OJQJ^JhAOJQJ^JhJhhAOJQJ^JsHhx8hAOJQJ^JsHhx8hAOJQJ^JhhAOJQJ^JhhA^JmH sH  hhA()))))********++++++$+.+t+++,,5,6,7,8,9,O,W,|,,,,,,,,,,κΫ{{l{{l{h$4h$4OJQJ^JtHh$4OJQJ^JmH sH tH$hx8h$4OJQJ^JmH sH tHhT=hJW^JmH sH h=hAOJQJ^JtH'hx8hA>*OJQJ^JmH sH tH$hx8hAOJQJ^JmH sH tHhAOJQJ^JmH sH tHhx8hAOJQJ^JtH*)))+6,7,8,9,,, -sYYY & F hhx]^h`gdkG*  'dQ]^* ` gdQV 'dQgd> & F xx]^x`gdkG & F xxx]^x`gdkG & F x]^`gdkG & F x]^`gdA ,--- -D-E---..`.a......////5/6/S/T///////////˻˨˨˨˨˨˻}pbphfRhD46OJQJ^JhfRhD4OJQJ^JhfRhD4OJQJ^JtHhh{xOJQJ^JtHh(h{x^JmH sH $hEFh$4OJQJ^JmH sH tHhl%OJQJ^JmH sH tH$hih$4OJQJ^JmH sH tHh$4h$4OJQJ^JtH$h.h$4OJQJ^JmH sH tH# -E-a.../6/T////>00vO 'd Q ]^O `gd>O ]^O `gd> 'dQ^` gd> & F hx]`gdkG & F xxx]^x`gdkG & F hhx]^h`gdkG //000(0*0=0>0i000011=1_111122s2t2u2v2w2̿}}}pf\OhfRh ^JmH sH h ^JmH sH hl^JmH sH hfRh{x^JmH sH hfRhl^JmH sH hfRh;<)^JmH sH hfRh{xOJQJ^JhfRh;<)6OJQJ^JhfRh;<)OJQJ^JhfRh*OJQJ^JhD4OJQJ^JhfRhD46OJQJ^JhfRhD4OJQJ^JhfRhD4OJQJ^JsH001t2u2v2w23_4{\ & F, xxx'dQ^x`gdkG & F, xxx'dQ^x`gdct 0 'dQ]^0 gd( 'dQgd> & F x'dQ^`gd>O x]^O `gd>]gdkGw233344^4_4t4u44455+5566677,7877777788888888999P9վվվ}}ph6hbOJQJ^JhhbOJQJ^JtHh 5^JmH sH h(h{x^JmH sH hkV%h6^JmH sH hkV%hct^JmH sH hctOJQJ^JmH sH hfRhct^J hfRhctOJQJ^JmH sH hfRhct^JmH sH hpuhct^JmH sH '_4u444+556877nT & F xxx]^x`gdct & F0 x'dQ^`gdct & F/ x'dQ^`gdct & F. xxx'dQ^x`gdct & F- hhx]^h`gdct & F- hhx]^h`gdkG77888889Q99:vva0 'd Q ]^0 gd>0 ]^0 `gd>0 'dQ^0 `gdQV0 'dQ^0 `gdct & F0 x]^`gdct xxx]^xgdct & F xx'd Q ]^x`gdct P9Q9h9i9r9999999999999:::: ::::":E:;ɿɿɿɿɦəre[RFRhvhb6]^Jhvhb^Jh hb5^JhovhbOJQJ^Jh&1hbOJQJ^JhvhbOJQJ^Jh8(hbOJQJ^Jh]+hbOJQJ^Jh6hb>*OJQJ^Jhb6OJQJ^JhbOJQJ^Jh6hbOJQJ^Jh\=hb6OJQJ^Jh\=hbOJQJ^JtHhb[hbOJQJ^J:: ;;p=q=r=s=>>v?r 0 0 x'd Q ]^0 gd> 0 ]gdkG 0 0 ]^0 `gdQV 0 0 ]^0 `gd> & F x'dQ^`gd>x^`gdb ]gdkG ;; ;;;;;;;<<<R<p<<<<<==o=p=q=r=s======ƹƬӟyncXPhctOJQJh,hctOJQJhJhhctOJQJh$1hctOJQJh\=hctOJQJh?pOJQJhvhKlOJQJhKlOJQJhXhb^JmH sH hJhhb^JmH sH hmhb^JmH sH hXhb^JmH sH hb^JmH sH h+hb^JmH sH h+hb^JmH sH hvhb^J===>>>>&>(>Z>[>p>q>r>>>>>>??v??@@@@@@AAAAGAJAAAA˛؁؁vihvhct^JmH sH h3hctOJQJhvhctOJQJmH sH h?phctOJQJhct5OJQJhvhct6OJQJ]^JhvhctOJQJ^JhctOJQJ^Jh[8BhctOJQJ^JhctOJQJh*hctOJQJh,hctOJQJhct6OJQJ%v??@@AAA B <$Ifgd 'dQgdkG 0 0 ]^0 gd> 0 ]gdkG & F 0 'd Q ]^`gd>" & F 0 x'd Q ]^`gd>AAAABB BBB/B0B6BSBTBdBBBBBBBBBBBBCCC6C7C=CuCvC|CCCCCCCCCCDD"D#D)DgDhDoDDD h.hI.hhI.OJQJ^JhnhI.OJQJ^JhchI.5OJQJ^JhbOJQJ^JhctOJQJ^JhhctOJQJ^J h.hct#hhct5OJQJ^JmH sH hhct5OJQJ^J5 BBB/Bti^ x$Ifgd $Ifgdkd$$Ifl400 ($h t 0`44 la pyt/B0B6BSBwla x$Ifgd $Ifgdkd$$Ifl00 ($h t 0`44 la pytSBTBdBBwla x$Ifgd $Ifgdkdj$$Ifl00 ($h t 0`44 la pytBBBBwla x$Ifgd $Ifgdkd $$Ifl00 ($h t 0`44 la pytBBBBwla x$Ifgd $Ifgdkd$$Ifl00 ($h t 0`44 la pytBBBBwla x$Ifgd $IfgdkdM$$Ifl00 ($h t 0`44 la pytBBC6Cwla x$Ifgd $Ifgdkd$$Ifl00 ($h t 0`44 la pyt6C7C=CuCwla x$Ifgd $Ifgdkd $$Ifl00 ($h t 0`44 la pytuCvC|CCwla x$Ifgd $Ifgdkd0 $$Ifl00 ($h t 0`44 la pytCCCCwla x$Ifgd $Ifgdkd $$Ifl00 ($h t 0`44 la pytCCCCCC"DwnnlaV x$Ifgd $Ifgd]gd>kdr $$Ifl00 ($h t 0`44 la pyt"D#D)DgDwla x$Ifgd $Ifgdkd $$Ifl00 &$j t 0`44 la pytgDhDoDDwla x$Ifgd $Ifgdkd $$Ifl00 &$j t 0`44 la pytDDDDwla x$Ifgd $Ifgdkdc $$Ifl00 &$j t 0`44 la pytDDDDDDDEE+E,E3EaEbEiEEEEEEEEEFF F@FAFQFtFuF{FFFFFFFGGGG G@GAGGGvGwGGGGGHHH HHBHCHQHvHwHHHHHHHHHķhK;VhKl^JmH sH hI.^JmH sH h.hI.CJOJQJ^JaJhn hI.OJQJ^J h.hI.hhI.OJQJ^JEDDDDwla x$Ifgd $Ifgdkd$$Ifl00 &$j t 0`44 la pytDDE+Ewla x$Ifgd $Ifgdkd$$Ifl00 &$j t 0`44 la pyt+E,E3EaEwla x$Ifgd $IfgdkdF$$Ifl00 &$j t 0`44 la pytaEbEiEEwla x$Ifgd $Ifgdkd$$Ifl00 &$j t 0`44 la pytEEEEwla x$Ifgd $Ifgdkd$$Ifl00 &$j t 0`44 la pytEEEEwla x$Ifgd $Ifgdkd)$$Ifl00 &$j t 0`44 la pytEE F@Fwla x$Ifgd $Ifgdkd$$Ifl00 &$j t 0`44 la pyt@FAFQFtFwla x$Ifgd $Ifgdkdk$$Ifl00 &$j t 0`44 la pyttFuF{FFwla x$Ifgd $Ifgdkd $$Ifl00 &$j t 0`44 la pytFFFFwla x$Ifgd $Ifgdkd$$Ifl00 &$j t 0`44 la pytFFFGwla x$Ifgd $IfgdkdN$$Ifl00 &$j t 0`44 la pytGG G@Gwla x$Ifgd $Ifgdkd$$Ifl00 &$j t 0`44 la pyt@GAGGGvGwla x$Ifgd $Ifgdkd$$Ifl00 &$j t 0`44 la pytvGwGGGwla x$Ifgd $Ifgdkd1$$Ifl00 &$j t 0`44 la pytGGGHuj_ x$Ifgd $Ifgdkd$$Ifl00 &$j t 0`44 la pytH HHBHuj_ x$Ifgd $Ifgdkdw$$Ifl00 &$j t 0`44 la pytBHCHQHvHf[P x$Ifgd $Ifgdkd$$Ifl00 &$j  t 0`44 la pytvHwHHHf[P x$Ifgd $Ifgdkd$$Ifl00 &$j  t 0`44 la pytHHHHf[P x$Ifgd $Ifgdkd$$Ifl00 &$j  t 0`44 la pytHHHHH2IuhSS< 0 0 x]^0 `gd>0 'dQ^0 `gdQV 'dQgdI.kde$$Ifl00 &$j t 0`44 la pytHHHII2IZIoIIIIJJ3J4J5JJJJJJKKfKgKKKKLLILLLMMMMMNNNNNNNN׵׏ׅwhfRhb5OJQJ^JhKlOJQJ^JhfRhkGOJQJ^JhfRhI.OJQJhfRhI.>*OJQJ^JhfRhI.OJQJ^JhI.5OJQJ^JhkGOJQJ^JhI.OJQJ^JhI.OJQJhhI.OJQJhKl5^JmH sH -2IZIoIIII4J5JJJJJfKgKKz 0 0 x]^0 gd> ]^`gd> 0 ]gdkG 0 0 ]^0 gd> ]gdkG & F+ ]^`gdkG & F+ x]^`gd>KLMMNNNNOOXPYP~q`q 0 0 ]^0 gd> 0 ]gdkG ]^`gd> ]gd,q ]gd> 0 0 x]^0 gd> ]gdkG & F ]^`gdkG & F x]^`gd> NNNNOOOOPPXPYPPPPQQQQiQjQoQwQQQRRRRRRRRRRRSSaSSTTETTUU)UVUϾϦϱxhzbhb^JmH sH hB^JmH sH hhb^JmH sH hb^JmH sH hb6OJQJ^JhhbOJQJ^J hFhbOJQJ^JmH sH hbOJQJ^Jh9hb>*OJQJ^Jh9hbOJQJ^Jhb5OJQJ^J/YPjQQRRRaSSETTsss & F" hhx'dQ^h`gd> & F xxx'dQ^x`gd>  & F x$xx'dQ^x`gd> & F+ x'dQ^`gd>0 x]^0 gdkG T)UVUvUUUUUVV WDWv & F5 ^`gd> & F1xx^x`gd> & F5 x^`gd>0 'dQ^0 `gdQV 'dQ^`gd> & F# XXx'dQ^X`gd> VUvUzU|UUUUUUVVBVVVVVWW W W=W>W?WDWEWeWWWWWWWWWWXXX6X7XUXVXXXXYYY1Y8YSY[YqYhI.^JmH sH hvhI.^JmH sH hK5^JmH sH hK;VhKl^JmH sH hGAhb^JmH sH hGAhb^JmH nH sH tH #hGAhb5^JmH nH sH tH hQphb5mH nH sH tH hhb^JmH sH 4DWWWWX7XVXXY{\ & F4 xxx'dQ^x`gd> & F5 x^`gd> & F xxx^x`gd> & F xxx'dQ^x`gd> x'dQ^gd>  ^gd> 'dQ^gd>qYYYZZZ{ZZZ[[)[h[\\\\\\\\]]c]]]]^^,^F^T^z^^^^__C_S_i_j_k_l_m___Ϝhh*OJQJ^Jhh*5OJQJ^Jh ^JmH sH hK;VhI.^JmH sH hvhI.0J-^JmH sH hK;VhK^JmH sH hK;Vhb^JmH sH h>LhI.^JmH sH hvhI.^JmH sH hI.^JmH sH .YYZ{ZZh[\\\\ooZ0 'dQ^0 `gdQV x'dQgd> & F4 xx'dQ^x`gdkG & F4 xxx^x`gd> & F4 xxx'dQ^x`gd> & F(hx'dQ^h`gd> & F(hx^h`gd> \c]]]],^F^T^z^^^C_S_vvv & F* xxx'dQ^x`gd> & F5 xx'dQ^x`gd> & F5 x'dQ^`gd> & F5 xx^x`gd> & F5 x^`gd> S_j_k_l_m_Z```wd 0 0 x]^0 gd> 0 0 'd Q ]^0 gd> 0 0 ]^0 `gd> x'dQgdQV0 'dQ^0 `gdQV0 'dQ^0 `gdI. & F* xx'dQ^x`gdkG_`` `Y`Z`g`p`w`````aa a aaaaaaabbb>b?bZbbbbccc;cccdcecfc|ccccccddLdMdddee+e,eķĪĐĐhnh*^JmH sH h*h*^JmH sH h3h*^JmH sH hh*^JmH sH h*^JmH sH hfRh*5^JmH sH hfRh*^JmH sH hh*OJQJ^Jh*OJQJ^J7` aaa?bZbbbbc;cdcecfctt 0 'dQ^0 `gd> & F 'dQ^gdkG & F x'dQ^`gd> x'dQ^`gd> & F x'dQ^`gdkG fcccMdd,e-efffoVV N N 'dQ^N `gd> 0 'dQ]^0 gd* 'dQgdkG & F 'dQ^`gdkG & F x'dQ^`gd> 'dQgd> 0 'dQ^0 `gd> ,e-egeeffffffff(fffggggggEgegkggggggghhķvl^lllQQh*NhkG^JmH sH h%hkG6^JmH sH hkG^JmH sH h*hkG^JmH sH hhkG6^JmH sH hhkG^JmH sH hhkG5^JmH sH h35^JmH sH h+h3^JmH sH hnh*^JmH sH h*6^JmH sH h*^JmH sH hh*^JmH sH hnhkG^JmH sH ffgggg_h`hahhhjjjjkk0 'dQ^0 `gdkG0 ^0 gdkG0 'dQ^0 gdkG 'dQgdkG N 0 'dQ^0 `gdkG N N 'dQ]^N `gdQVh1h3hMhNh]h^h_h`hahehthuhhhi iiii4iAieijjjejjjjjjk kkk9k>kHkekrkskkkkkkkkkkkkζΩΜΎĄhD4^JmH sH h%hkG6^JmH sH hD4hkG^JmH sH hhkG^JmH sH hhkG5^JmH sH hkG^JmH sH hhkG^JmH sH hOZY^JmH sH hkhkG6^JmH sH h*NhkG^JmH sH 4kkkkkmmHnIn\nmnsx$If]gdCx$If]gdC0 'dQ^0 gdY 'dQgdY0 'dQ^0 `gdY0 'dQ^0 `gdQV0 'dQ^0 `gdkG0 'dQ^0 gdkG kkl ldlmdmmmmnnnHnIn\ndnmnnnnnnnnnnnnoo&o'o8oGoHo_odonoooʹ}}pppcch@hYOJQJ^Jh_hYOJQJ^JhFhYOJQJ^Jh%hYOJQJ^JhhYOJQJ^JhhY5mH nH sH tH hhY>*OJQJ^JhY\^JmH sH hhY\^JmH sH hhY^JmH sH hhY5^JmH sH hD4^JmH sH &mnnnnnnnnHSkd^$$Ifl0 v$ 644 la0 ytCx$If]gdCSkd $$Ifl0 v$ 644 la0 ytCnnnnno&oHSkd$$Ifl0 v$ 644 la0 ytCx$If]gdCSkd$$Ifl0 v$ 644 la0 ytC&o'o8oGoHo_onoHSkd$$Ifl0 v$ 644 la0 ytCx$If]gdCSkdZ$$Ifl0 v$ 644 la0 ytCnooooooooHSkdV$$Ifl0 v$ 644 la0 ytCx$If]gdCSkd$$Ifl0 v$ 644 la0 ytCooooooooooooppppppp p p p p ppppppppp!p"p#p$p%pº~i\hfR5CJOJQJ^J(hfR0J5CJOJQJ^JmHnHuhfR0J5CJOJQJ^J&jhfR0J5CJOJQJU^JhfROJQJ^JhfR5OJQJ^Jh}jh}UhS^hKl^JmH sH hY^JmH sH hi$hYOJQJ^JhhYOJQJ^Jh@94hYOJQJ^J#oooooopHSkd$$Ifl0 v$ 644 la0 ytCx$If]gdCSkd$$Ifl0 v$ 644 la0 ytCppppp p p pppppp%pr !5&dP]5  !5]5 'dQgdx 'dQgdYSkdR$$Ifl0 v$ 644 la0 ytC %p&p'p(p/p0pJpKpLpRpSpTpUpVpWpXpdpxppppppȽzdXNNNNDNhK;VCJOJQJhfRCJOJQJhfR0JOJQJ^J*hcthfR0J5CJOJQJ\^JaJ+hY0J5CJOJQJ\^JmHnHu hfR0J5CJOJQJ\^J)jhfR0J5CJOJQJU\^J hfR5CJhfR5CJOJQJhcthfR5OJQJ\^JhfR5OJQJ\^J,jhfR5OJQJU\^JmHnHuhfR%p&p'p0pVpWpXpxpppppp{vgd`$ !]a$gd= !$]gd`gdQV$ !0]0a$gdQV !$]gdQVgd<' !$]gd<' !$&dP]gd<' $]a$gd<' ppppppppppppppppppppq qqqqqqq%q&qӿ|rk^ӿhfR5OJQJ\^J hQVhfRhYCJOJQJhJKhfROJQJ^J#hcthfR5CJOJQJ^JaJ(hY0J5CJOJQJ^JmHnHuhfR0J5CJOJQJ^J&jhfR0J5CJOJQJU^JhfROJQJ^JhfR5OJQJ^JhfRhfRCJOJQJhc]~CJOJQJpppppppp qqqqq)q*qz !5&dP]5gdQV$ !0]0a$gdQV !$]gdQVgd`$ !]a$gd= !$]gd` !&dP]gdbN  !5]5&q'q(q)q*q1q2q3q9q:q;qq?q_qdqhqiqqqqqqqqqqqqqqqqqƻע׍{nddddZdZdƻע׍{nhBCJOJQJhfRCJOJQJhJKhfROJQJ^J#hcthfR5CJOJQJ^JaJ(hY0J5CJOJQJ^JmHnHuhfR0J5CJOJQJ^JhfROJQJ^JhfR5OJQJ^JhfRhfR5CJOJQJ^J&jhfR0J5CJOJQJU^J(hfR0J5CJOJQJ^JmHnHu"*q2q=q>q?q_qhqiqqqqqu  !5]5gd 1gd`$ !$]a$gd= !$]gd`gdQV$ !0]0a$gdQV !$]gdQVgd+$ !&dP]a$gd+$ !]a$gd&G qqqqqqqqqqqrro$ !0]0a$gdQV !$]gdQVgd`$ !$]a$gd= !$]gd`  !$] !p&&dP $^`a$gd 1 !&dP]gd 1 qqqqqqqqqqqqqqqqqqrrrrrrr!r"r#r$rӾӾӜzjӾT+hY0J5CJOJQJ\^JmHnHuhcthfR5OJQJ\^Jhc]~CJOJQJh CJOJQJhfRCJOJQJhfRhfR0JOJQJ^J+hc]~0J5CJOJQJ\^JmHnHu)jhfR0J5CJOJQJU\^J hfR0J5CJOJQJ\^JhfR5CJOJQJ\^JhfR5OJQJ\^Jrrr%r&r'rGrPrQrpryrzrzugd`$ !]a$gd= !$]gd`$ !0]0a$gdQV !$]gdQV  !$]$ !$&dP]a$gd $]^`a$gdbNgdQV $r%r&r'rGrPrQrdrprxryrzrrrrrrrrrrrrrrrrrrrrrrrڹm`VڹhD4CJOJQJhJKhfROJQJ^J+hY0J5CJOJQJ\^JmHnHu hfR0J5CJOJQJ\^J)jhfR0J5CJOJQJU\^JhcthfR5OJQJ\^JhfR5OJQJ\^JhACJOJQJhfRCJOJQJhfRhfR0JOJQJ^J*hcthfR0J5CJOJQJ\^JaJ!zrrrrrrrrrrrsngdQV$ !0]0a$gdQV !$]gdQVgd`$ !]a$gd= !$]gd` !&dP]gd{xgd{x !$&dP]gd{x]^`gd{x rrrrrs&s's/s:s;stFtRtStTt !$&dP]gd{xgd{x !$]gdct]^`gd{xgd`$ !]a$gdI. !$]gdI.  !$]sssssttt t t t tttt/ttEtFtGtMtNtPtQtRt˶yl]G+hc]~0J5CJOJQJ\^JmHnHuhfR5CJOJQJ\^Jh|,hfROJQJ^J*hcthfR0J5CJOJQJ\^JaJ+hY0J5CJOJQJ\^JmHnHu hfR0J5CJOJQJ\^J)jhfR0J5CJOJQJU\^JhcthfR5OJQJ\^JhfR5OJQJ\^JhfRhfRCJOJQJhI.CJOJQJRtStTt[t\t]tctdtftgthtitjttttttttttttttttttttòÜÆzppi__pòÜÆRphJKhfROJQJ^JhI.CJOJQJ hQVhfRhfRCJOJQJhfR0JOJQJ^J*hcthfR0J5CJOJQJ\^JaJ+hY0J5CJOJQJ\^JmHnHu hfR0J5CJOJQJ\^J)jhfR0J5CJOJQJU\^JhcthfR5OJQJ\^JhfR5OJQJ\^JhfR h{xhfRTt\thtitjttttttttzhcgd`$ !]a$gdI. !$]gdI.$ !0]0a$gdi;7gdQV$ !0]0a$gdQV !$]gdQV  !$]$ !$&dP]a$gd $]^`a$gdbN ttttttuu uuuu{o  !$]$ !$&dP]a$gd $]^`a$gdbNgd`$ !]a$gd= !$]gd`gd{x !$&dP]gd{x]^`gd{x ttuuuu u u uuuuuuuu:uCuDucudupuquruyuzu{uuuuuuocYYYohI.CJOJQJhfR0JOJQJ^J*hcthfR0J5CJOJQJ\^JaJ+hY0J5CJOJQJ\^JmHnHu hfR0J5CJOJQJ\^J)jhfR0J5CJOJQJU\^JhcthfR5OJQJ\^JhfR5OJQJ\^JhfRhKlCJOJQJhfRCJOJQJhbCJOJQJu:uCuDucuquruzuuuuuuuuugd{x !$&dP]gd{x]^`gd{xgd`$ !]a$gdI. !$]gdI.gdQV$ !0]0a$gdQV !$]gdQVuuuuuuuuuuuuuuuuuuuuuvvvvοΒ}l}V}@*hcthfR0J5CJOJQJ\^JaJ+hY0J5CJOJQJ\^JmHnHu h90J5CJOJQJ\^J)jh90J5CJOJQJU\^JhcthfR5OJQJ\^JhfR0JOJQJ^J hfR0J5CJOJQJ\^JhfR5CJOJQJ\^JhfR5OJQJ\^JhfRCJOJQJhI.CJOJQJhfRhJKhfROJQJ^Juuuuuuuvvv#v,vr`$ !0]0a$gdQV !$]gdQV  !$]$ !$&dP]a$gd $]^`a$gdpgdx !$]gdx !$&dP]gdx]^`gdxgdQV v#v,v-vLvOvSvTvUvVv]v^v_vdvevfvhvivjvkvlvsvtvwvxvyvv˶ym^MmChI.CJOJQJ hfR0J5CJOJQJ\^JhfR5CJOJQJ\^JhfR0JOJQJ^J*hcth90J5CJOJQJ\^JaJ+hY0J5CJOJQJ\^JmHnHu h90J5CJOJQJ\^J)jh90J5CJOJQJU\^JhcthfR5OJQJ\^JhfR5OJQJ\^JhrKCJOJQJhfRhfRCJOJQJ,v-vLvUvVv^vjvkvlvtvwvxvrf  !$] !$&dP]gdt]^`gdt !$]gdx !$&dP]gd9]^`gdxgd`$ !]a$gd= !$]gd`gdQV xvyvvvvvvvvvvvvz$ !]a$gdx !$]gdx  !$]$ !$&dP]a$gd $]^`a$gdtgd`$ !]a$gdI. !$]gdI. vvvvvvvvvvvvvvvvvvvvv˶ymcYOK>hS^hKl^JmH sH h}h1CJOJQJhYCJOJQJhxCJOJQJhfR0JOJQJ^J*hcthfR0J5CJOJQJ\^JaJ+hY0J5CJOJQJ\^JmHnHu h90J5CJOJQJ\^J)jh90J5CJOJQJU\^JhcthfR5OJQJ\^JhfR5OJQJ\^JhfRhfRCJOJQJhkGCJOJQJvv 'dQgdx6&P1:p / =!"#$%(8 2&P:p / =!"#$%(8 6&P1:p / =!"#$%(8 6&P1:p / =!"#$%(8 6&P1:p / =!"#$%(8 6&P1:p / =!"#$%(8 6&P1:p / =!"#$%(8 6&P1:p / =!"#$%(8 6&P1:p / =!"#$%(8 6&P1:p / =!"#$%(8 6&P1:p / =!"#$%(8 6&P1:p / =!"#$%(8 6&P1:p / =!"#$%(8 6&P1:p / =!"#$%(8 6&P1:p9/ =!"#$%(8 C0P&P1:p / =!"#$%(8 Dp6&P1:p9/ =!"#$%(8 =DyK yK http://files.medi-cal.ca.gov/pubsdoco/publications/masters-mtp/part2/enteralnutrition.xlsyX;H,]ą'cX$$If !vh#v#vI:V l t655Ia ytuX$$If !vh#v#vI:V l t655Ia ytuX$$If !vh#v#vI:V l t655Ia ytuX$$If !vh#v#vI:V l t655Ia ytuX$$If !vh#v#vI:V l t655Ia ytuX$$If !vh#v#vI:V l t655Ia ytuX$$If !vh#v#vI:V l t655Ia ytuX$$If !vh#v#vI:V l t655Ia ytuX$$If !vh#v#vI:V l t655Ia yt=*X$$If !vh#v#vI:V l t655Ia yt=*X$$If !vh#v#vI:V l t655Ia yt=*$$If !vh#v#vh:V l4 t 0`,55ha pyt$$If !vh#v#vh:V l t 0`55ha pyt$$If !vh#v#vh:V l t 0`55ha pyt$$If !vh#v#vh:V l t 0`55ha pyt$$If !vh#v#vh:V l t 0`55ha pyt$$If !vh#v#vh:V l t 0`55ha pyt$$If !vh#v#vh:V l t 0`55ha pyt$$If !vh#v#vh:V l t 0`55ha pyt$$If !vh#v#vh:V l t 0`55ha pyt$$If !vh#v#vh:V l t 0`55ha pyt$$If !vh#v#vh:V l t 0`55ha pyt$$If !vh#v#vj:V l t 0`55j/ a pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pyt$$If !vh#v#vj:V l  t 0`55ja pyt$$If !vh#v#vj:V l  t 0`55ja pyt$$If !vh#v#vj:V l  t 0`55ja pyt$$If !vh#v#vj:V l t 0`55ja pytR$$If0 !vh#v #v:V l65 5a0 ytCR$$If0 !vh#v #v:V l65 5a0 ytCR$$If0 !vh#v #v:V l65 5a0 ytCR$$If0 !vh#v #v:V l65 5a0 ytCR$$If0 !vh#v #v:V l65 5a0 ytCR$$If0 !vh#v #v:V l65 5a0 ytCR$$If0 !vh#v #v:V l65 5a0 ytCR$$If0 !vh#v #v:V l65 5a0 ytCR$$If0 !vh#v #v:V l65 5a0 ytCR$$If0 !vh#v #v:V l65 5a0 ytCR$$If0 !vh#v #v:V l65 5a0 ytC2w002 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@6666_HmH nH sH tH 8`8 Normal_HmH sH tH HH  Heading 1$@&  5OJQJV@V + Heading 2$@& 5>*OJQJmHsHtH@@  Heading 3$@& >*OJQJZZ  Heading 4!$ (#L@&^L >*OJQJZZ  Heading 5!$ (#L@&^L 5OJQJJJ  Heading 6$ (#@&OJQJjj  Heading 7!$ (#@&^5>*OJQJWKwf\\\  Heading 8$$@&]^a$5>*OJQJ\V V  Heading 9 $@&^`5>*OJQJ\DA`D Default Paragraph FontVi@V  Table Normal :V 44 la (k (No List 4@4 Header  !>/> ( Header Char_HmH sH tH 4 @4 Footer  !>/!> ( Footer Char_HmH sH tH .)@1. Page Number>' A> Comment ReferenceCJ4R4 , Comment TextPTbP Block Text0 ]^0 `OJQJ<& q< Footnote ReferencefCf Body Text Indent# (#`^``OJQJ6U`6 Hyperlink >*B*ph<Z< Plain Text OJQJ^JDjQRD Comment Subject 5CJ\\B@\ 00 Body Text'd Q ]OJQJmHsHtHHH  Balloon TextCJOJQJ^JaJFV F FollowedHyperlink >*B* phB0B List Bullet  & FCJaJF6F List Bullet 2 & FCJaJF7F 0 List Bullet 3 ! & FCJaJF8"F List Bullet 4 " & FCJaJF92F List Bullet 5 # & FCJaJB1BB List Number $ & FCJaJF:RF List Number 2 % & FCJaJF;bF List Number 3 & & FCJaJF<rF List Number 4 ' & F CJaJF=F List Number 5 ( & F CJaJ*W * Strong5\jRj Body Text Indent 2*0 P7$8$H$^0 OJQJ\^JaJB/B eDHeading 2 Char5>*OJQJ:/: 4Comment Text Charo 4st1< <40Revision._HmH sH tH `` w\ List Paragraph /^ CJOJPJQJ^JaJnHtH</< ^X0Body Text CharOJQJjj bH] Table Grid7:V101PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭VGRU1a$N% ʣꂣKЛjVkUDRKQj/dR*SxMPsʧJ5$4vq^WCʽ D{>̳`3REB=꽻Ut Qy@֐\.X7<:+& 0h @>nƭBVqu ѡ{5kP?O&Cנ Aw0kPo۵(h[5($=CVs]mY2zw`nKDC]j%KXK 'P@$I=Y%C%gx'$!V(ekڤք'Qt!x7xbJ7 o߼W_y|nʒ;Fido/_1z/L?>o_;9:33`=—S,FĔ觑@)R8elmEv|!ո/,Ә%qh|'1:`ij.̳u'k CZ^WcK0'E8S߱sˮdΙ`K}A"NșM1I/AeހQתGF@A~eh-QR9C 5 ~d"9 0exp<^!͸~J7䒜t L䈝c\)Ic8E&]Sf~@Aw?'r3Ȱ&2@7k}̬naWJ}N1XGVh`L%Z`=`VKb*X=z%"sI<&n| .qc:?7/N<Z*`]u-]e|aѸ¾|mH{m3CԚ .ÕnAr)[;-ݑ$$`:Ʊ>NVl%kv:Ns _OuCX=mO4m's߸d|0n;pt2e}:zOrgI( 'B='8\L`"Ǚ 4F+8JI$rՑVLvVxNN";fVYx-,JfV<+k>hP!aLfh:HHX WQXt,:JU{,Z BpB)sֻڙӇiE4(=U\.O. +x"aMB[F7x"ytѫиK-zz>F>75eo5C9Z%c7ܼ%6M2ˊ 9B" N "1(IzZ~>Yr]H+9pd\4n(Kg\V$=]B,lוDA=eX)Ly5ot e㈮bW3gp : j$/g*QjZTa!e9#i5*j5ö fE`514g{7vnO(^ ,j~V9;kvv"adV݊oTAn7jah+y^@ARhW.GMuO "/e5[s󿬅`Z'WfPt~f}kA'0z|>ܙ|Uw{@՘tAm'`4T֠2j ۣhvWwA9 ZNU+Awvhv36V`^PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!g theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK]  VR9$w*1s5;@FMTmW^cn8l܈L,dԊ D !R|$9c    !Kttt!!!6Lw  8888Nd>lll'PPPfsD p("g$'(),/w2P9;=ADHNVUqY_,ehkoo%pp&qq$rrMssRttuvvv<>@ACDFGJQTUWYZ\^`cefhwD 76CVRmO$') -0_47:v? B/BSBBBBB6CuCCC"DgDDDD+EaEEEE@FtFFFG@GvGGHBHvHHH2IKYPTDWY\S_`fcfkmnn&onoop%pp*qqrzrrDssTttuu,vxvvv=?BEHIKLMNOPRSVX[]_abdgijklmnopqrstuvxyz{|}~?bnXELN!,35|)02?FH@GJV]` t{~X_b!t!4!t!t!t!t!4!4!4!4!4!4!4!4!4!4!4!4!4!4!4!4@ I I@ H (  V H 3 #" ?0(  B S  ?!H $&t _Hlt414260229 _Hlt414260230TTn@@UUn'-/79@al/58><:R:::>!>'b.bffgggghh h h hhhhhnnn)*:;Cy 6 f &XQ9;NRTd !112 3OOOPMUSUvU~U^]^__` ddn3333333  TVPR6$>(>(((t*v*w*0001q5s5;;@@FFMMTTkWmW^^cchhhhh h h h h hhhhhh$h%h(h)h+h/hAhJhXhhhhhhhii*i2ii?ihiiiiiiiiij$jjjjj/k9kEkOkkkl lFlQl\lglll mmzmmmn^ninnnnn  TVPR6$>(>(((t*v*w*0001q5s5;;@@FFMMTTkWmW^^cchhhh h h h hhhhh(h)h+h/hAhJhXhhhhhhhi*i2ii?ihiiiiiiiiijjj$jjjjj/k9kEkOkkkl lFlQl\lglll mmzmmmn^ninnnnn5|"f(}>_'~GP&j%/\E#\;"D! ʭ$lO'fH:\7&t X2 L%-,\ ې`~$p!#FqHWWn [#1 \"Sk "5X64):'t"l*jo|T.`߸z0hS65X-=kXjAXDxHlaMI^JL-4#K<vKKz_@K7`R(tjU(/@8VN4+#0b b:)8d}@b|f X}Y"jg/]Frp}cs詢M1tq,t"Bsk-uP/&BBu[obvBn ~v|G%Px0^-xB*M|9x~%^^`.^`.88^8`.^`. ^`OJQJo( ^`OJQJo( 88^8`OJQJo( ^`OJQJo(hh^h`. hh^h`OJQJo(^`OJPJQJ^Jo( ^`OJQJ^Jo(hHo^`OJQJo(hH`^``OJQJo(hH0^0`OJQJ^Jo(hHo^`OJQJo(hH ^ `OJQJo(hH#^#`OJQJ^Jo(hHop&^p&`OJQJo(hHh ^`hH.h ^`hH.h L^`LhH.h l^l`hH.h <^<`hH.h  !L^ !`LhH.h #^#`hH.h &^&`hH.h |)L^|)`LhH. h^h`o(hH7 ^`o(hH)8^8`CJOJQJo(hHv ^`o(hH() ^`o(hH() p^p`o(hH()  ^ `o(hH. @ ^@ `o(hH.  ^ `o(hH.h@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh  ^ `OJQJo(hHh^`OJQJ^Jo(hHoh!!^!`OJQJo(hHh h^h`o(hH ^`hH) 8^8`hH) ^`hH() ^`hH() p^p`hH()  ^ `hH. @ ^@ `hH.  ^ `hH.hh^h`OJQJo(hHh ^`o(hH. 8^8`hH) ^`hH() ^`hH() p^p`hH()  ^ `hH. @ ^@ `hH.  ^ `hH.0 ]^]`OJQJo(0 e^e`OJQJ^Jo(hHo0 5^5`OJQJo(hH0 ^`OJQJo(hH0 ^`OJQJo(hH0 ^`o(hH.0 u!^u!`OJQJo(hH0 E$^E$`OJQJ^Jo(hHo0 '^'`OJQJo(hH^`OJQJ^Jo(hH ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.h ^`o(hH.h^`OJQJ^Jo(hHoh^`OJQJo(hHhp^p`OJQJo(hHh@^@`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh"^"`OJQJ^Jo(hHoh%^%`OJQJo(hHh ^`OJQJo(h^`OJQJ^Jo(hHoh^`OJQJo(hHhp^p`OJQJo(hHh@^@`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh"^"`OJQJ^Jo(hHoh%^%`OJQJo(hH0 ]^]`OJQJo(0 e^e`OJQJ^Jo(hHo0 5^5`OJQJo(hH0 ^`OJQJo(hH0 ^`OJQJo(hH0 ^`o(hH.0 u!^u!`OJQJo(hH0 E$^E$`OJQJ^Jo(hHo0 '^'`OJQJo(hHh.h^h`567B*CJOJQJS*o(phhH ^`hH) 8^8`hH) ^`hH() ^`hH() p^p`hH()  ^ `hH. @ ^@ `hH.  ^ `hH.0 ]^]`OJQJo(0 e^e`OJQJ^Jo(hHo0 5^5`OJQJo(hH0 ^`OJQJo(hH0 ^`OJQJo(hH0 ^`OJQJ^Jo(hH0 u!^u!`OJQJo(hH0 E$^E$`OJQJ^Jo(hHo0 '^'`OJQJo(hH0 ]^]`OJQJo(0 e^e`OJQJ^Jo(hHo0 5^5`OJQJo(hH0 ^`OJQJo(hH0 ^`OJQJo(hH0 ^`o(hH.0 u!^u!`OJQJo(hH0 E$^E$`OJQJ^Jo(hHo0 '^'`OJQJo(hHhh^h`OJQJo(hHh ^`o(hH. 8^8`hH) ^`hH() ^`hH() p^p`hH()  ^ `hH. @ ^@ `hH.h ^ `OJPJQJ^Jo(hH  h^h`o(hH7 ^`hH)h8^8`CJOJQJo(hHv ^`hH() ^`hH() p^p`hH()  ^ `hH. @ ^@ `hH.h  ^ `o(hH. h^h`o(hH7 ^`hH)h8^8`CJOJQJo(hHv ^`hH() ^`hH() p^p`hH()  ^ `hH. @ ^@ `hH.h  ^ `o(hH.hh^h`OJQJo(hHh ^`o(hH. 8^8`hH) ^`hH() ^`hH() p^p`hH()  ^ `hH. @ ^@ `hH.h  ^ `o(hH^`OJQJ^Jo(hH ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.h,^,`OJQJo(hHh ^`o(hH.h L^`LhH.h ^`hH.h l^l`hH.h <L^<`LhH.h  !^ !`hH.h #^#`hH.h &L^&`LhH.hh^h`OJQJo(hHh ^`o(hH. 8^8`hH) ^`hH() ^`hH() p^p`hH()  ^ `hH. @ ^@ `hH.  ^ `hH.h,^,`OJQJo(hHh ^`o(hH.h L^`LhH.h ^`hH.h l^l`hH.h <L^<`LhH.h  !^ !`hH.h #^#`hH.h &L^&`LhH.h,^,`OJQJo(hHh^`CJaJo(hH.h L^`LhH.h ^`hH.h l^l`hH.h <L^<`LhH.h  !^ !`hH.h #^#`hH.h &L^&`LhH.h^h`OJQJo(hH ^`o(hH. 8^8`o(hH) ^`o(hH() ^`o(hH() p^p`o(hH()  ^ `o(hH. @ ^@ `o(hH.  ^ `o(hHh X^X`o(hH.(^(`OJPJQJ^Jo(-h L^`LhH.h ^`hH.h ^`hH.h hL^h`LhH.h 8"^8"`hH.h %^%`hH.h 'L^'`LhH.hX^X`OJPJQJ^Jo( h(^(`OJPJQJ^Jo(hH h^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohh^h`OJQJo(hHh8"^8"`OJQJo(hHh%^%`OJQJ^Jo(hHoh'^'`OJQJo(hHhh^h`OJQJo(hHh ^`o(hH. 8^8`hH) ^`hH() ^`hH() p^p`hH()  ^ `hH. @ ^@ `hH.  ^ `hH..h^h`567B*CJOJQJS*o(phhH ^`o(hH) 8^8`o(hH) ^`o(hH() ^`o(hH() p^p`o(hH()  ^ `o(hH. @ ^@ `o(hH.  ^ `o(hH.h h^h`o(hHh ^`o(hH. 8^8`hH) ^`hH() ^`hH() p^p`hH()  ^ `hH. @ ^@ `hH.h  ^ `o(hHhh^h`OJQJo(hH ^`hH)8^8`CJaJo(hH. ^`hH() ^`hH() p^p`hH()  ^ `hH. @ ^@ `hH.  ^ `hH.h X^X`o(hH.h (^(`hH.h L^`LhH.h ^`hH.h ^`hH.h hL^h`LhH.h 8"^8"`hH.h %^%`hH.h 'L^'`LhH.hh^h`OJQJo(hH ^`hH)h^h`CJaJo(hH. ^`hH() ^`hH() p^p`hH()  ^ `hH. @ ^@ `hH.  ^ `hH.h,^,`OJQJo(hHh ^`o(hH.h L^`LhH.h ^`hH.h l^l`hH.h <L^<`LhH.h  !^ !`hH.h #^#`hH.h &L^&`LhH. ^`o(hH ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.h,^,`OJQJo(hHh^`CJaJo(hH.h L^`LhH.h ^`hH.h l^l`hH.h <L^<`LhH.h  !^ !`hH.h #^#`hH.h &L^&`LhH.h ^`hH.h ^`hH.h L^`LhH.h l^l`hH.h <^<`hH.h  !L^ !`LhH.h #^#`hH.h &^&`hH.h |)L^|)`LhH.h h^h`o(hH. ^`hH) 8^8`hH) ^`hH() ^`hH() p^p`hH()  ^ `hH. @ ^@ `hH.  ^ `hH.h,^,`OJQJo(hHh^`CJaJo(hH.h L^`LhH.h ^`hH.h l^l`hH.h <L^<`LhH.h  !^ !`hH.h #^#`hH.h &L^&`LhH.  ^ `OJQJo(^`.L^`L.^`.n^n`.>L^>`L.^`.!^!`.$L^$`L.h^`OJQJo(hHh^`OJQJ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJQJo(hHh,^,`OJQJo(hHh^`CJaJo(hH.h L^`LhH.h ^`hH.h l^l`hH.h <L^<`LhH.h  !^ !`hH.h #^#`hH.h &L^&`LhH.0 ]^]`OJQJo(0 e^e`OJQJ^Jo(hHo0 5^5`OJQJo(hH0 ^`OJQJo(hH0 ^`OJQJo(hH0 ^`o(hH.0 u!^u!`OJQJo(hH0 E$^E$`OJQJ^Jo(hHo0 '^'`OJQJo(hHh ^`o(hH.h^`OJQJ^Jo(hHoht^t`OJQJo(hHhD^D`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh"^"`OJQJo(hHh%^%`OJQJ^Jo(hHohT(^T(`OJQJo(hH5~}| ~v2 *M|%PxBBu#0bb|f-=8d*Sk "}cs#1 ]Fr~$jARz0,\ x~WWxH@K\7M1tvK^-xMIobv|T.Fq4):'65-4#Kt Y"jjU,t'@8Vk-u b55G                                     d                                        d            G   [~                 RD           "       (F`2       GG         []d        RD         &TDs                            \>9                          V<\                          s 9j*q4/SgJe )Xi6jsmD~(4nY_f}O+"/MBz[wA=CavF* M19aXD~S FAqUe (z V l  \ ~  # q w w +|,.+34=p';;[%9_@jW E"d/!!B`iuYy(H/KA]Fd;z~nLT.c^_ak`.1=3iQ 6@GX| s  8!+<"n"#}.#OE#P#$A<$>$N$_%;7%kV%) & &=&e&Os&u' ''();<)=<)?)md)* *=*_*+,Z,k,)s,X-.f*.H.O.///H0QL0111 ?1Q1u2pw2|27)3OF3t3$454@@4D4w45"5OO5=w5M 66-696^6i;7?7!8x8V|8V9wh9'K:|i:N;u;*<D<'W<=(=`G=>R>x>%?Hn?@<A$A+AEGBaSB `BpnB.VCqkCrDD#DGD^DeD}DE E@5FmF&GkGHH>VH\HvEJ4KBKJKPiKrKwKLnM}M~M2N^NtOPxP Q/QJQ[Q R0=SYSfS;Ty T_T#jTWUSkUK;VSzbC^X#FrT^]AWasD#4G{=Ac/Zx 5Rq =Goq~,bXk!T= !KbN@[i+bwa1q|{1CRVX>9^*S.G=F||fRnr3 PWkw +AHrxM^pC]#\/rr2YZ"^vD Thlzp <JWvQx ''6f$_%l% 1AaVCj Y!W{ )CHwi6B-jxz3`S LI.=sIIgw1bF~<'gDq>*}Gs:"hr6rlX;?K_Hxw6gj 5<Q,ty `u  :#kN'3QGj.fEn}J'#]c~5E'?;_Nl01_9JuU%NXr}(?Lby%?Kr?ANNW|hi'oiKQVOct'0B$-j5wpu`{A[t.,E?p~n#-}qMubo;XBP[h+D!I*W]1<<&\]uytzhh@^`^`^`n@Unknown G.[x Times New Roman5Symbol3. .[x Arial7..{$ Calibri?= .Cx Courier New5. .[`)Tahoma;(SimSun[SOC.,*{$ Calibri Light;WingdingsA$BCambria Math#qhLe܂2f X5X5&d4gg OqHX  ?W\2+! xx'X5 $Enteral Nutrition Products (enteral) Cruze, Hannah5                           ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 Oh+'0h|     (Enteral Nutrition Products (enteral)lNew section (06.2012) split from previous Enteral Nutrition: List of Available Products section JT pgs. 1-9 (06.08.12) New section (enteral) JT pg. 9 (07.29.13) JT pg. 8 (12.09.13) JT pg. 9 (12.27.13) JT pgs. 1-9, 10-11 new (03.28.14) JT pg. 2 (07.29.14) BS pg. 11 (10.30.14) JT pgs. 3, 8-11, 12 new (12.24.14) JT pgs. 1-12, 13-17 new (03.10.15) JT pgs. 6, 10, 16 (04.08.15) JT pg. 17 (05.06.15) JT pgs. 7-10, 15 (09.01.15) ICD10 JT pgs. 3, 4 (11.03.15) AW pg. 2 (12.04.15) MiR pg. 4 (05.09.16) JT pgs. 8, 10-12, 17 (01.30.17) JT pgs. 5, 8, 9, 12-14, 17 (03.16.17) PE4PW JT pg. 3 (04.03.17) no policy updates, transparent edit to March Pharmacy Priority JT pgs. 1, 4, 10, 15, 16 (05.25.17) HC pgs. 7, 9-11, 13, 14, 16, 17 (11.27.17) SE pg. 17 (05.29.18) HC pg. 17 (12.27.18) TL pgs. 5, 17 (05.29.19) BA pgs. 2, 16, 17 (08.07.19) TL pg. 16 (02.27.20) Normal.dotmCruze, Hannah12Microsoft Office Word@J6@Ls@rd@uX ՜.+,D՜.+,T hp  CA-MMIS5g %Enteral Nutrition Products (enteral) Title`(X`T _PID_HLINKS_NewReviewCycleA\Zhttp://files.medi-cal.ca.gov/pubsdoco/publications/masters-mtp/part2/enteralnutrition.xls  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./012356789:;=>?@ABCHILRoot Entry F QSK@Data 1Table+WordDocument SummaryInformation(4DocumentSummaryInformation8<MsoDataStore`|Q?RDT2O2A==2`|Q?RItem  PropertiesUCompObj r   F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q